HCW Biologics lands US patent with senotherapeutic potential

LT Staff

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Clinical-stage immunotherapy company HCW Biologics (NASDAQ: HCWB) was granted a new US patent which contains methods of use claims directed to administering the company’s clinical-stage bifunctional immunotherapeutic to treat cancer. However, the patent also includes methods of use claims for killing or reducing the number of senescent cells in cancer patients.

Accumulation of senescent cells modifies the microenvironment in tissues and organs and creates chronic, sterile inflammation, which drives aging and age-related diseases. This patent boosts HCW’s position in the field of inflammaging – the company is focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grade inflammation and age-related diseases.

HCW’s lead compound, HCW9218, is currently being evaluated in two initial-stage clinical trials with the primary objectives to determine safety, maximum tolerated dose, and the recommended Phase 2 dose. The company believes the Phase 1/1b studies will be completed in 2023.

“This patent supports our commitment to treat diseases driven by chronic inflammation typical of aging and age-related diseases, including cancer,” said Dr Hing C Wong, CEO of HCW Biologics. “These diseases are promoted by cellular senescence and the proinflammatory factors they secrete, known as SASP factors. We believe that HCW9218 has the potential to redefine the approach for treating aging conditions and age-related diseases by alleviating senescence with an immunotherapeutic therapy that rejuvenates the immune system.”

HCW recently published a scientific paper in Aging Cell entitled, “Immunotherapeutic approach to reduce senescent cells and alleviate senescence-associated secretary phenotype in mice.”

“The publication of our scientific paper in Aging Cell followed by the issuance of this patent for methods of treating age-related disorders is noteworthy,” said Wong. “These events acknowledge that we may have found a novel method for the treatment of cancer and other age-related disorders.”

Photograph: Freepik

LTUI: 2196

HCW Biologics

Longevity level(s):

Level 6: Aging disease prevention therapeutics
Therapeutic interventions that control aging drivers to prevent aging diseases from occurring, like the current wave of GLP-1 agonists that prevent type 2 diabetes through metabolic interventions that also are proving effective in mitigating cardiovascular and neurological diseases.
Level 8: Systemic aging reversal
Therapeutic interventions that stop or reverse age-related damage throughout the whole body system at a cellular level. Including technologies such as mitochondrial transplant, senotherapeutics and partial cellular reprogramming.

Overview

Country: United States
Website
Company LinkedIn

HCW Biologics is a clinical-stage biopharmaceutical company developing proprietary immunotherapies designed to address chronic, low-grade inflammation and age-related diseases through disruption of inflammaging pathways. The company leverages its proprietary TOBI™ (Tissue factOr-Based fusIon) and TRBC discovery platforms to engineer multi-functional fusion molecules that modulate immune responses, targeting conditions including cancer, autoimmune diseases, and age-related disorders. By focusing on the intersection of immunotherapy and longevity, HCW Biologics aims to extend healthspan through cellular rejuvenation and senescent cell clearance mechanisms.